Selecta Biosciences Inc. - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים RNAC

Cartesian Therapeutics (RNAC) is implementing AI-powered automated bioreactors to scale RNA therapy. Current trailing 12-month revenue dynamics confirm this progress, with the metric recorded at 0.00. Exclusive patents and strict FDA oversight serve as a moat, although the lack of stable income and high production costs create significant financial survival risks for the company.

The unique RNA platform of Cartesian Therapeutics (RNAC), which eliminates genomic integration, establishes the foundation for the commercialization of autoimmune disease therapies. The current annual sales growth rate (trailing 12 months) at 0.00 reflects TTM revenue dynamics relative to the previous year, allowing investors to assess the actual speed of business scaling and avoid purchasing the asset at the indicator's peak.